Doctor woman  working with a microscope Scientific Microscope. Medical health care research concept background.

Valenta Labs

Share this:

dna and medical and technology background. futuristic molecule structure presentation. for business solutionViravaxx provides novelties in hard-to-treat viral infections, such as respiratory syncytial virus (RSV) and rhinovirus (RV), which have resisted vaccination approaches for a long time. To this end, Viravaxx collaborates with the Valenta Labs at the Medical University of Vienna. The Valenta labs exploit technology to convert non-immunogenic epitopes of surface proteins essential for the virus life cycle to potent immunogens. In addition, the Valenta labs develop multiplexed tools for high resolution serum immune diagnostics.


SARS-CoV-2 Interaction Assay
Together with the Valenta Labs at the Medical University of Vienna, Viravaxx recently developed an interaction assay mimicking SARS-CoV-2 binding to its receptor ACE2. The assay is used in an ongoing clinical trial to analyze neutralizing antibody responses. The read-out of the assay is an antibody signature to assess protective immunity of patients enrolled in the trial.

Source: Allergy, 2020,